These words define abstract as existing in thought, or as an idea, not having a physical or concrete existence.

USCAP defines abstract as the synoptic summary of your intellectual focus or research investigation. Convert your thought or idea into something concrete.

Requirements

Scientific material must be original and not previously published, nor currently accepted for publication or presentation at another meeting prior to the USCAP 2021 Annual Meeting.

Abstract Fee

There is a $50 non-refundable processing fee for each abstract submission.

Submission Deadline

The deadline to submit abstracts is Thursday, October 29, 2020 at 3:00 PM Eastern Daylight Time.

Virtual Presentation

The 2021 USCAP Annual Meeting will be virtual. Authors of abstracts accepted as posters will be asked to submit a short PowerPoint presentation rather than a printed or digital poster. This presentation will be pre-recorded and allow the presenter to emphasize the poster highlights. These short summary presentations will be available for attendees to view online for the duration of the meeting. Presenters will be assigned a presentation time during which they must be available to answer questions about their abstracts. No actual posters will be produced for 2021.

USCAP Embargo Policy

Unless otherwise noted, all abstracts presented at the USCAP Annual Meeting are embargoed until the date and time of presentation. They cannot be presented in any national or international forum or be published (online of print) in abstract or manuscript form prior to first day of the USCAP annual meeting. USCAP reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during the USCAP Annual Meeting.

Eligibility Requirements

Scientific material must be original. It cannot be previously published in abstract or manuscript form. It also cannot be currently accepted for publication or presentation at another meeting prior to the USCAP 2021 Annual Meeting, March 13-18, 2021. Authors may submit as many abstracts as they wish; there is no limit to the number of co-authored abstracts. However, no more than three abstracts will be accepted from any first author. If more than three first-author abstracts are submitted, the lowest scoring abstract(s) will be immediately rejected. Abstracts are reviewed in a blinded fashion. Please do not include any identifying information such as institutional names or specific names for institutional assays in the body of the abstract. View the complete rules and submission guidelines below.

All abstracts submitted to the USCAP 2021 Annual Meeting must meet the eligibility requirements below:

  • Scientific material must be original.
  • Abstracts are not eligible for consideration if the abstract has been presented at a major national or international meeting prior to the USCAP 2021 Annual Meeting, March 13-March 18, 2021.
  • Abstracts cannot be previously published, online or in print, prior to the USCAP 2021 Annual Meeting, March 13-March 18, 2021.
  • If the accepted abstract is also submitted as a manuscript for publication prior to the USCAP 2021 Annual Meeting, the authors are responsible for coordinating with the journal to determine a publication date that abides by USCAP’s embargo policy. Abstracts related to manuscripts that are published online or in print before the USCAP 2021 Annual Meeting, March 13-March 18, 2021, must be withdrawn. Please notify the Academy via e-mail at support@uscap.org.
    • If authors choose to submit a manuscript to Modern Pathology or Laboratory Investigation prior to the abstract presentation at the USCAP 2021 Annual Meeting, March 13-March 18, 2021, they will need to indicate this on the submission form and in the cover letter for the journal submission. USCAP has an agreement with these journals to withhold approved manuscripts from publication until the embargo is lifted.
  • All abstracts must follow USCAP’s embargo policy. Any abstract found to be presented or published prior to the USCAP 2021 Annual Meeting, March 13-March 18, 2021 will be removed from the program.
  • USCAP will examine all abstracts with anti-plagiarism software to verify the originality of the work. Flagged abstracts will be manually reviewed and those that represent only an incremental advance or lack sufficient novelty compared with published abstracts will be rejected.

Author Eligibility

  • Individuals may submit as many abstracts as they wish; however, no more than three abstracts will be accepted from any first author. If more than three first-author abstracts are submitted, the lowest scoring abstracts will be immediately rejected.
  • Individuals may serve as a coauthor on an unlimited number of abstracts.
Submission Requirements

 Contact Information

All authors must provide a full name, academic degree(s), institution, address (including city, state, and country), and email address. Only the first author and primary contact will receive future correspondence from USCAP regarding the status of the abstract.

To ensure all authors are able to receive email correspondence from USCAP, please add the following domain to your email software.

  • xcdsystem.com

Co-Authors

  • The full name, institution, city, state, country, and email is required for all co-authors.
  • Upon entry of an author, an automatic email will be sent from the system requesting the author login and complete a disclosure. Authors can complete their disclosures at any point after being added to the system, up to the closure of the submission website on Thursday, October 29, 2020 at 3:00 PM Eastern Daylight Time. 
  • First authors who submit abstracts for consideration as platform presentations are responsible for ensuring that all authors complete their disclosure. Failure to complete disclosures prior to the submission deadline (Thursday, October 29, 2020 at 3:00 PM Eastern Daylight Time) will result in removal of the abstract from consideration for a platform presentation and automatically default to the “poster-only” category.
  • Authors who do not receive email communications from USCAP can simply login to the system, scroll down to locate the abstract, and select the Disclosures button. A red Disclosures button indicates that the disclosure(s) is incomplete.

Abstract Title

  • The abstract title must be in Title Case.
    • Capitalize the first word of the title.
    • Capital letters should be used for all nouns, verbs, adjectives, adverbs, pronouns, and subordinate conjunctions (e.g. because, although). All other words, including articles, coordinate conjunctions (e.g. and, or, but), and prepositions should be lowercase.
    • Do use lowercase and uppercase letters in instances when they have specific meanings (e.g. mCEA, HER2).
  • Do not include a period at the end of the title.
  • The maximum length of the abstract title is 40 words.

    EXAMPLE

    Correct: Utility of p53 and mCEA Immunostaining in Biliary Cytology Specimens
    Incorrect: Utility of p53 and mcea Immunostaining in biliary cytology specimens.

    Abstract Content

    • The maximum length of the abstract is 2,500 characters (including spaces). This includes the background, design, results, and conclusion. Abstracts that do not fit in the defined space are automatically truncated. Authors should review their final abstracts as they appear on the website prior to submission. There is no limit on the number of authors. Authors and their affiliations do not count toward the character count of the abstract.
    • The abstract should be divided into the following: Background, Design, Results, and Conclusion. The submission program allows authors to enter information for each of these sections and displays the headers on the final abstract form in this manner. These headings appear automatically – do not type them in. Abstracts are blinded for review. Please do not include identifying information in the body of the abstract (e.g. institutional names or assays).
    • Tables and figures are permitted in addition to text allotments described above. Guidelines are below:
      • Figures
        • Maximum of 2 figures per abstract submission
        • Width – 6 inches
        • Height – no more than 4 inches tall
        • Maximum file size cannot exceed 3MB
        • Images must be high resolution, 300 DPI, RGB
        • Only jpg (jpeg) or png formats are allowed
        • Patient Photos
          Do not submit patient photos unless the patient has granted permission. Documentation of permission must be provided to USCAP prior to the abstract submission. Failure to provide documentation of permission will lead to the removal of the photograph from the online abstract and publication. Submit documentation to education@uscap.org. Include the abstract ID and title in the email. All photos must be deidentified.
        • Device Photos
          Do not submit device photos. All photos of devices will be removed from the online abstract and publication.
        • Uploaded figures can be replaced by uploading a different file to the same location. They can also be deleted by selecting the Delete Figure button. NOTE: The Delete Figure button will only appear after the abstract has been saved.
      • Table
        • Maximum of 1 table per abstract submission. Text in the table will not deduct from the character count.
        • Width – 6 inches
        • Height – no restrictions
        • Font – sans serif, no less than 5pt
    • Standard abbreviations are acceptable. A special abbreviation should be placed in parentheses after the first appearance of the full word for which it stands. Greek and mathematical symbols are provided in the character map within the program.
    • Generic drug names are preferred and should be written without capital letters. If a proprietary drug name is used, the first letter should be capitalized.
    • Abstracts can be edited up to the point of the submission deadline and closure of the abstract submission site on Thursday, October 29, 2020 at 3:00 PM, Eastern Daylight Time. There is no final submit button.
    • Abstract revisions cannot be made after the submission deadline. It is recommended that authors login to the system and double check the work prior to the submission deadline. Changes cannot be made after the deadline.

      Presentation Type

      Check Poster Only or Either Poster or Platform on the Submit Abstract page. Abstracts submitted for “poster” or platform presentation will be assigned a final presentation type by the Abstract Assignment Committee. Assignments are based on a combination of scientific merit and the Committee’s opinion regarding its most effective presentation method.

      The 2021 USCAP Annual Meeting will be virtual. No actual posters will be produced for 2021.

      Poster Presentations – Abstracts accepted for poster only presentations will be asked to submit a short PowerPoint presentation and recording of the poster highlights (up to 10 slides with a 3-minute video). Presenters will be assigned a presentation time where they must be available to answer questions about their abstract. Additional details and instructions for the submission of slides and recording will be available in early January. No posters will be produced for 2021.

      Platform Presentations – Abstracts accepted for a platform presentation will be asked to submit a short PowerPoint and ten (10) minute recording of the poster highlights. Presenters will be assigned a presentation time where they must be available to answer questions. Each platform presenter will be allowed five (5) minutes for Q&A. Additional details and instructions for the submission of slides and recording will be available in early January.

      Category

      Abstracts must be submitted in one of the categories listed below. Abstracts submitted to an inappropriate category will be reassigned accordingly. See Category Descriptions for detailed information.

      • Autopsy and Forensics
      • Bone and Soft Tissue Pathology
      • Breast Pathology
      • Cardiovascular Pathology
      • Cytopathology
      • Dermatopathology
      • Education
      • Endocrine Pathology
      • Gastrointestinal Pathology
      • General Surgical Pathology
      • Genitourinary Pathology (including renal tumors)
      • Gynecologic and Obstetric Pathology
      • Head and Neck Pathology
      • Hematopathology
      • Infectious Disease Pathology
      • Informatics
      • Liver Pathology
      • Medical Renal Pathology (including renal transplantation)
      • Neuropathology and Ophthalmic Pathology
      • Pancreas, Gallbladder, Ampulla, and Extra-Hepatic Biliary Tree
      • Pathobiology and Emerging Techniques
      • Pediatric and Perinatal Pathology
      • Pulmonary, Mediastinum, Pleura, and Peritoneum Pathology
      • Quality and Patient Safety

      Abstracts may be moved from the category of submission to another category by the Abstract Assignment Committee as appropriate.

      Awards

      Stowell-Orbison Awards and Autopsy or Surgical Pathology Awards for Pathologists-in-Training

      Application information must be completed online through the abstract submission system. In order to be eligible for these awards, applicants must meet all of the following requirements:

      • First author must be a pathologist-in-training
      • Applicants can submit only one first-author abstract for award consideration
      • Upload a verification of eligibility

      Detailed award information is available here: https://www.uscap.org/stowell-orbison-awards/

      Abstracts accepted for consideration of Stowell-Orbison Awards, Surgical Pathology Awards, and Autopsy Pathology Awards will be presented during the virtual meeting. In 2021, presenters will not submit a poster. Abstracts accepted for inclusion in the Stowell-Orbison session will be asked to submit a short PowerPoint and recording of the poster highlights (up to 10 slides with a 3-minute video). These short summary presentations will be available for attendees to view online for the duration of the meeting. The award committees will determine the finalists and the presenters will be assigned a presentation time where the finalists must be available to answer questions about their abstract. Additional details and instructions for the submission of slides and recording will be available in early January. Abstracts that are submitted for this competition, but not accepted, will automatically be considered for acceptance as regular abstracts according to subspecialty.

      Category Descriptions

      Autopsy and Forensics: This category includes abstracts describing pathology related to adult autopsy. It excludes abstracts describing pediatric autopsy, fetal pathology, and autopsy-related neuropathology.

      Bone and Soft Tissue Pathology: This category includes abstracts describing neoplastic and non-neoplastic diseases of soft tissues and bone. It does not include abstracts describing cutaneous soft tissue tumors or mesenchymal tumors of the gastrointestinal tract.

      Breast Pathology: This category includes abstracts describing neoplastic and non-neoplastic diseases of the breast. Abstracts describing mesenchymal tumors and hematopoietic disorders of the breast are included.

      Cardiovascular Pathology: This category includes abstracts describing neoplastic and non-neoplastic diseases of the heart and blood vessels. Cardiac transplantation pathology is included.

      Cytopathology: This category includes abstracts describing neoplastic and non-neoplastic diseases of all sites encountered in exfoliative or fine needle aspiration samples.

      Dermatopathology: This category includes abstracts describing neoplastic and non-neoplastic diseases of the skin. Abstracts describing cutaneous mesenchymal and hematopoietic tumors are included.

      Education: This category includes abstracts describing innovation and application of existing platforms (e.g. social media) to pathology education. Topics may be related to specific organ systems or general anatomic pathology.

      Endocrine Pathology: This category includes abstracts describing diseases of the thyroid gland, parathyroid glands, adrenal glands, and paraganglia. It does not include abstracts describing disorders of the pancreas, endocrine tumors of the gastrointestinal tract, or pituitary diseases.

      Gastrointestinal Pathology: This category includes abstracts describing neoplastic and non-neoplastic diseases of the tubular gastrointestinal tract. Abstracts describing mesenchymal tumors (e.g. gastrointestinal stromal tumor), hematopoietic tumors, and bowel transplantation pathology are included. This category excludes abstracts describing diseases of the gallbladder, pancreas, liver, ampulla, and extrahepatic biliary tree.

      General Surgical Pathology: This category includes abstracts describing neoplastic and non-neoplastic diseases that are not limited to one organ system (e.g. molecular analysis of squamous cell carcinomas from different sites, or novel immunohistochemical markers that have diagnostic applications to multiple sites).

      Genitourinary Pathology: This category includes abstracts describing neoplastic diseases of the kidneys, as well as both neoplastic and non-neoplastic disorders of the ureters, urinary bladder, prostate, penis, and testis. This category does not include abstracts describing medical renal disease or transplantation pathology.

      Gynecologic Pathology: This category includes abstracts describing neoplastic and non-neoplastic diseases of the ovaries, fallopian tubes, uterus, cervix, vagina, and vulva. It also includes abstracts describing placental and obstetric pathology. It does not include abstracts describing primary peritoneal neoplasms.

      Head and Neck Pathology: This category includes abstracts describing neoplastic and non-neoplastic diseases of the oral cavity, nasopharynx, paranasal sinuses, larynx, and salivary glands. It does not include abstracts describing cutaneous diseases of the face or disorders of the thyroid and parathyroid glands.

      Hematopathology: This category includes abstracts describing neoplastic and non-neoplastic diseases of lymph nodes, bone marrow elements, spleen, and dendritic cells. It does not include thymoma or thymic carcinoma. Abstracts describing disorders involving specific sites (e.g. skin, gastrointestinal tract, central nervous system) may be more appropriately submitted to other categories.

      Infectious Disease Pathology: This category includes abstracts describing non-neoplastic diseases of an infectious etiology that affect multiple organs or organ systems. Abstracts describing disorders confined to one organ or organ system (e.g. pulmonary fungal infections) and those discussing pathogen-driven neoplasia may be more appropriately submitted to other categories.

      Informatics: This category includes abstracts describing issues related to pathology information systems, digital pathology, data analysis, information technology, machine learning, and similar topics. Abstracts describing application of these techniques to pathology education or diseases of one organ and/or one organ system may be more appropriately submitted to other categories.

      Liver Pathology: This category includes abstracts describing neoplastic and non-neoplastic diseases of the liver. Liver transplantation pathology and tumors and inflammatory conditions of the intrahepatic bile ducts are included. Disorders of the extrahepatic bile ducts and gallbladder are excluded.

      Medical Renal Pathology: This category includes abstracts describing issues related to non-neoplastic renal diseases as well as transplantation pathology. It does not include abstracts describing neoplastic diseases of the kidney.

      Neuropathology and Ophthalmic Pathology: This category includes abstracts describing neoplastic and non-neoplastic diseases of the central nervous system and its coverings, pituitary gland, and eye. Autopsy neuropathology is included. Abstracts describing myopathies and peripheral neuropathies are included.

      Pancreas, Gallbladder, Ampulla and Extra-hepatic Bile Ducts: This category includes abstracts describing neoplastic and non-neoplastic diseases of the pancreas, gallbladder, ampulla, and extra-hepatic bile ducts up to the hilum. Endocrine/neuroendocrine tumors of the pancreas and pancreatic transplantation pathology are included.

      Pathobiology and Emerging Techniques: This category includes abstracts that emphasize disease biology or describe issues related to oncogenesis and pathogenesis of non-neoplastic conditions and highlight new assays and platforms that may have diagnostic or prognostic value in the pathologic assessment of human diseases. Pan-genomic/pan-proteomic approaches and ultrastructural pathology are generally included, although abstracts describing application of these techniques to diseases of one organ or one organ system may be more appropriately submitted to other categories.

      Pediatric and Perinatal Pathology: This category includes abstracts describing neoplastic and non-neoplastic diseases of the pediatric population, perinatal diseases, and fetal autopsies.

      Pulmonary, Mediastinum, Pleura, and Peritoneum: This category includes abstracts describing neoplastic and non-neoplastic diseases of the tracheobronchial tree, lungs, pleura, and mesothelial surfaces of the peritoneal cavity. It also includes thymoma, thymic carcinoma, and mediastinal germ cell tumors. It does not include lymphomas.

      Quality and Patient Safety: This category includes abstracts describing the study of risk to patients in pathology as well as failure to meet standards of timeliness, report accuracy, and transfer of materials between services. It includes abstracts describing baseline data collection followed by an intervention and analysis of post-implementation data.

      Abstracts may be moved from the category of submission to another category by the Abstract Assignment Committee as appropriate.

      Financial Disclosures

      USCAP has zero tolerance for any commercial bias in abstracts and the content must be presented objectively. Reviewers are instructed to reject any abstract which does not meet these criteria.

      • Each author must complete an Author Disclosure Form for each abstract submitted; this can be done as soon as the author has been added to an abstract. The abstract does NOT need to be final in order to submit a disclosure.
      • Upon entry of an author, an automatic email is sent from the system requesting the author login and complete a disclosure. The first author is responsible for ensuring all authors complete their disclosures.
      • No abstract will be accepted for a platform presentation without completed disclosure forms from ALL authors. Authors must note any relevant relationships with companies in the event that their products and/or services are discussed in the abstract. All relationships, or absence of relationships, must be disclosed to the audience.

      As an accredited provider of continuing medical education (CME) by the Accreditation Council for Continuing Medical Education (ACCME), USCAP complies with the Standards for Commercial Support. To ensure the CME activities USCAP offers are independent and free of commercial bias, the USCAP CME Subcommittee reviews all disclosures from all authors on accepted abstracts that were submitted for platform presentation consideration. If there is not a reasonable way to resolve the conflicts of interest on an abstract, the abstract presentation preference may be changed to poster only. This decision is made by the CME Subcommittee following a thorough review of the disclosures and the abstract content.

      This policy is not intended to prevent authors with commercial relationships from making a presentation. Disclosure of relevant relationships is required to help maintain objectivity and allow audience members to form their own judgments regarding the merit of material presented with the benefit of full disclosure of facts. Relationships that are not relevant to the content of the abstract need not be disclosed.

      Policy on Unlabeled/Off-Label Use
      USCAP has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). USCAP requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. All references to unlabeled/off-label use of products in the abstract must be disclosed on the poster when presented.

      Abstracts from Industry
      Abstracts that are accepted will be presented as posters and must only display research findings. No advertising or product identification by brand name is allowed. Commercial, product, and company logos cannot be placed on posters or poster boards. Posters that contain any type of commercial promotion, as described above, will be removed from the poster hall immediately without notice to the presenter.

      All posters presented by industry must include a disclosure statement.

      Abstract Fee

      There is a $50 non-refundable processing fee for each abstract submission. Credit card payment must be made by selecting the Payment button. Payment must be made in order to complete the submission process. The abstract submission fee does not include general registration. If accepted, the presenting author of the abstract must register for the 2021 USCAP Annual Meeting.

      Notification of receipt will be emailed to the primary contact following the payment. NOTE: It is the responsibility of the author to contact USCAP if confirmation of abstract receipt is not received within 1 business day. USCAP will confirm receipt of the abstract or assist authors to ensure that the abstract is complete.

      Submission Deadline and Notifications

      Deadline

      Only electronic submissions of original work will be accepted. To be eligible for review:

      • Submission must be received by Thursday, October 29, 2020 at 3:00 PM Eastern Daylight Time
      • The abstract fee must be paid prior to the abstract deadline. If the payment is not received by the deadline, the abstract will be withdrawn.
      • All authors and co-authors on abstracts submitted for platform presentation must have completed an Author Disclosure Form for each abstract. Failure to complete disclosures prior to the submission deadline will result in removal of the abstract from consideration for a platform presentation.
      • In the interest of fairness, these guidelines must be respected by all potential authors.

      Notifications

      Notification of acceptance or rejection will be sent to the first author and primary contact by e-mail in early December; authors will not receive any notifications by mail. A second notification specifying presentation type and further details about the presentation will be sent to the first author and primary contact in early January. Authors who do not receive an e-mail by mid-January should login to the Abstract Submission site with the login credentials used to create the submission and select the View Final Status button.

      If an abstract is accepted, the presenting author is required to register for the USCAP 2021 Annual Meeting and pay the general registration fee. Online registration will be available on the USCAP website in November 2020. All registrations must be completed online. Register early as fees for early registration are discounted.

      Publication of Abstracts in Modern Pathology and Laboratory Investigation

      All abstracts accepted for presentation at the 2021 USCAP Annual Meeting are published in an online-only supplement of Modern Pathology and Laboratory Investigation. The supplement will be released on Monday, March 15, 2021.

      Abstract Withdrawal

      The primary contact or first author may withdraw an abstract by contacting USCAP Education at education@uscap.org with the request. Abstracts withdrawn after January 18, 2021 will not be included in the online program but will be published in the Modern Pathology and Laboratory Investigation journal supplements.

      USCAP Embargo Policy

      Unless otherwise noted, all abstracts accepted for presentation at the USCAP Annual Meeting are embargoed from submission until the date and time of presentation. They cannot be presented in any national or international forum or be published (online or print) in abstract or manuscript form prior to the first day of the USCAP annual meeting. USCAP reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during the USCAP Annual Meeting.

      If the accepted abstract is also submitted as a manuscript for publication, authors are responsible for coordinating a publication date that abides by the Academy’s embargo policy. If publication occurs online or in print before the USCAP 2021 Annual Meeting, March 13-18, 2021, the abstract must be withdrawn. Please notify the Academy via e-mail at support@uscap.org.

      Frequently Asked Questions

      What is the abstract submission deadline?

      Abstract submissions will open on Thursday, August 6, 2020. Abstracts are due Thursday, October 29th at 3:00 PM Eastern Daylight Time. A completed abstract must include the following:

      • Abstract Title, Background, Design, Results, and Conclusion
      • Completed Payment
      • To be considered for a platform presentation, all author disclosures must have been completed. Each author will need to submit a disclosure for each abstract.
      How do I get my login information to submit an abstract?
        • Emails regarding login information or disclosures may be blocked by your institutions spam blocker. Please ask your institution’s Information Technology staff to “white list” any emails coming from uscap.org and xcdsystem.com.
        • In order to login visit the abstract submission site and enter your email address and password.
        • If you do not remember your password, click Reset Password on the submission login page. If you no longer have access to the email associated with your account, please email support@uscap.org or call USCAP offices: at +1-706-733-7550
      How do I update my contact information?
      • Once you are logged in, click Profile Home in the upper left of the abstract submission site, then select Manage My Account.
      • Select the Update Profile button at the bottom to save your changes.
      Do I need to add section headings or are they added automatically?
      No, you do not need to add section headings. The headers (Background, Design, Results, Conclusion) will be added automatically in the publication of abstracts.
      How do I edit my abstract?
      • Login to the abstract submission site and select the Edit Abstract button to make necessary changes.
      • Then click the Update Abstract button to save your changes.
      • There is no final submit button. Abstracts can be edited up until the submission deadline on Thursday, October 29 at 3:00 PM Eastern Daylight Time.
      How do I edit or delete a figure/image?
      • To edit a figure/image: select the figure you would like to edit, and upload a new file. The new file will override the existing file.
      • To delete a figure: select the delete figure button under the figure and scroll to the bottom and select Update Abstract. Note, the delete figure button will only appear after the abstract has been saved.
      Do images or tables take away from the character limit?

      No. Authors will have 40 words to complete the abstract title. Authors will have 2500 characters (including spaces) to complete the abstract background, design, results, and conclusion. Text in the results table will not deduct from the character count.

      I did not receive an email to complete my disclosure, how do I complete it?
      • Emails may be blocked by your institutions spam blocker. Please ask your institutions Information Technology staff to white list any emails coming from uscap.org and xcdsystem.com.
      • Also, co-authors may login to complete their disclosures.
      • Once logged in, click on the 2021 Annual Meeting Abstract Submission button
      • Then scroll down and click on the Author Disclosure button. It will be red if the disclosure(s) are incomplete.
      • Follow the prompts to complete and submit your disclosure.
      How do I complete disclosures as primary presenter?
      • Once you have submitted your abstract, the Disclosure button will turn red and become active.
      • Select this button and follow the prompts to complete your disclosure.
      • You cannot complete disclosures for the co-authors on your abstract. Each of the co-authors will need to login to the system and complete their own disclosures.
      • To be considered for a platform presentation, all author disclosures must be completed before the site closes on Thursday, October 29 at 3:00 PM Eastern Daylight Time. If any author disclosures are missing at the time of closure of the submission website, the abstract will automatically default to a poster presentation.
      How do I see which co-authors have completed their disclosures?

      Only primary presenters can check the status of co-author disclosures. Follow the steps below to find out which co-authors have completed their disclosures.

      • Login to view your abstract
      • Once logged in, click on 2021 Annual Meeting Abstract Submission
      • Scroll down to view your abstract
      • Select View Disclosures
      • A screen will pop-up showing all the co-authors and their disclosure status
      • To be considered for a platform presentation, all author disclosures must have been completed.
      How do I pay for and submit my abstract?
      • Visit the login page.
      • Enter your email address and password to login.
      • Once you are logged in, click on the 2021 Annual Meeting Abstract Submission button.
      • Scroll down and click on Payment
      • Follow the prompts to enter your payment information and submit.
      • The submission fee for each abstract is $50 USD.
      • A abstract submission is not considered Complete until the submission fee is paid. After paying the submission fee, you can still update your abstract until the deadline: Thursday, October 29, 2020 at 3:00 PM Eastern Daylight Time.

      NOTE: There is no final submit button. Once the payment and all author disclosures are received, the abstract is considered complete. You may edit your abstract until the submission site closes on Thursday, October 29, 2020 at 3:00 PM Eastern Daylight Time.

      How do I get a receipt for my payment?
      • Visit the login page.
      • Enter your email address and password to login.
      • Once you are logged in, click on the 2021 Annual Meeting Abstract Submission button.
      • Scroll down and click on Payment Receipt.